Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Genprex, Inc. is a clinical-stage biotechnology company focused on developing gene-based therapies for patients with cancer and diabetes. The company operates within the biopharmaceutical and gene therapy industries, with a strategic emphasis on using tumor suppressor genes and other genetic payloads delivered via non-viral systems to address diseases with high unmet medical need. Genprex does not currently generate commercial revenue and is primarily funded through equity financing and strategic collaborations.
The company’s core programs center on Reqorsa® (quaratusugene ozeplasmid), a plasmid DNA therapy designed to restore tumor suppressor gene function or modify disease pathways at the genetic level. Genprex positions itself as a translational medicine company that advances therapies through academic and clinical partnerships, leveraging externally conducted research and clinical trials. Genprex was founded in 2009 and became publicly traded in 2018, evolving from an early research-focused entity into a clinical-stage organization advancing multiple human trials.
Business Operations
Genprex conducts operations through a single reportable business focused on gene therapy research and development, with activities spanning preclinical research, clinical trial oversight, regulatory engagement, and intellectual property management. Its lead oncology program, Reqorsa Oncology, targets non-small cell lung cancer (NSCLC) and has been evaluated in combination with approved therapies such as chemotherapy and immune checkpoint inhibitors. A separate program, Reqorsa Diabetes, is being developed for type 1 and type 2 diabetes using a gene therapy approach intended to improve pancreatic beta cell function and insulin production.
The company does not maintain large-scale internal laboratory or manufacturing operations, instead relying on contract research organizations, contract manufacturing organizations, and academic collaborators. Genprex has established sponsored research and clinical collaborations with institutions including The University of Texas MD Anderson Cancer Center and The University of Texas Southwestern Medical Center. All programs remain in clinical or preclinical development, and no products have received regulatory approval to date.
Strategic Position & Investments
Genprex’s strategy is centered on advancing Reqorsa® through clinical development while expanding its pipeline into additional indications using the same non-viral gene delivery platform. The company has emphasized combination therapy strategies, particularly in oncology, where its gene therapy is designed to enhance the effectiveness of existing standard-of-care treatments. Growth initiatives focus on advancing clinical trial phases, securing additional development partnerships, and expanding intellectual property coverage.
The company has entered into collaboration and license agreements related to its gene therapy technologies rather than pursuing acquisitions of commercial-stage assets. Genprex has disclosed ongoing evaluation of emerging applications of gene therapy in metabolic and oncologic diseases; however, expansion beyond its current programs is limited by capital availability. Data inconclusive based on available public sources regarding any late-stage acquisition plans or binding commercial partnership agreements beyond research collaborations.
Geographic Footprint
Genprex is headquartered in the United States, with its principal executive offices in Texas. Its operational footprint is primarily domestic, reflecting its reliance on U.S.-based academic medical centers, clinical trial sites, and regulatory engagement with the U.S. Food and Drug Administration.
While the company does not maintain international offices, its clinical development activities have the potential for global reach through multinational trials and future licensing arrangements. At present, international operations and revenue contributions are minimal, and the company’s influence outside North America is primarily indirect through scientific publication and intellectual property filings.
Leadership & Governance
Genprex is led by executives with backgrounds in biotechnology commercialization, corporate finance, and clinical development. The leadership team emphasizes disciplined capital management, partnership-driven development, and a focus on advancing genetically targeted therapies for serious diseases with limited treatment options.
Key executives include:
- Rodney Varner – President, Chief Executive Officer, and Chairman of the Board
- Ryan Confer – Chief Financial Officer
- Mark Berger – Chief Medical Officer
- Shelley Roden – Senior Vice President, Operations
The board of directors includes individuals with experience in biotechnology, healthcare investment, and corporate governance, supporting oversight of strategy, risk management, and regulatory compliance.